P2RX4 and COVID-19: Ivermectin, which is known to potentiate the activity of the purinergic receptor P2X4 (88), which can form heterotrimeric receptors with P2X7 (89), was recently found to inhibit the replication of SARS-CoV-2 in vitro (90), but did not show benefits for COVID-19 patients (91).